Online citations, reference lists, and bibliographies.
← Back to Search

Solid Lipid Nanoparticles As Drug Carriers. I. Incorporation And Retention Of The Lipophilic Prodrug 3′-azido-3′-deoxythymidine Palmitate

H. Heiati, R. Tawashi, R. Shivers, N. Phillips
Published 1997 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Solid lipid nanoparticles (SLN) were prepared with trilaurin (TL) as the SLN solid core and dipalmitoylphosphatidylcholine (DPPC) or a mixture of DPPC and dimyristoylphosphatidylglycerol (DMPG) to produce neutral and negatively charged SLNs. The ester prodrug of 3′-azido-3′-deoxythimidine (Zidovudine®, AZT) with palmitic acid, AZT palmitate (AZT-P), was synthesized and its incorporation and retention in SLNs determined. The incorporation of hydrophilic AZT in SLNs was minimal; however the incorporation of AZT-P increased with increasing phospholipid (PL) content and was independent of the amount of TL used. The incorporation of AZT-P was greater in negatively charged SLNs than in neutral SLNs. The in vitro release of AZT-P from different SLNs formulation was studied at 37°C using a bulk-equilibrium reverse dialysis sac technique. Increased drug release was observed in SLNs formulated with PLs having a transition temperature below 37°C. The results obtained indicate that the highly packed TL core of the SLN is not compatible with lipophilic molecules such as AZT-P. The incorporation and subsequent retention of AZT-P appears to be dependent on the PL coating on the SLNs surface and is independent of the TL solid core.
This paper references
10.1248/CPB.35.1214
Partition characteristics and retention of anti-inflammatory steroids in liposomal ophthalmic preparations.
K. Taniguchi (1987)
10.3109/02652049509015290
An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride.
N. Magalhães (1995)
10.1021/JM00128A017
Nucleic acid related compounds. 57. Synthesis, x-ray crystal structure, lipophilic partition properties, and antiretroviral activities of anomeric 3'-azido-2',3'-dideoxy-2,6-diaminopurine ribosides.
M. J. Robins (1989)
10.1021/BI00507A007
Thermotropic behavior of bilayers formed from mixed-chain phosphatidylcholines.
S. Chen (1981)
10.1182/blood.v79.5.1137.bloodjournal7951137
Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome.
N. Phillips (1992)
Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.
K. Hostetler (1990)
10.1093/JAC/31.1.161
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
D. Caillot (1993)
10.1016/S0923-2494(92)80167-J
Stimulation of Kupffer cell tumoricidal activity by liposomal muramyl dipeptides.
N. Phillips (1992)
10.1016/0378-5173(90)90381-D
Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model
M. Y. Levy (1990)
10.1016/0005-2760(80)90131-9
The stability of liposomes in vitro to pH, bile salts and pancreatic lipase.
R. Rowland (1980)
Temperature and compositional dependence of the structure of hydrated dimyristoyl lecithin.
M. J. Janiak (1979)
10.1016/0006-291X(90)91414-N
Lipid conjugates of antiretroviral agents. I. Azidothymidine-monophosphate-diglyceride: anti-HIV activity, physical properties, and interaction with plasma proteins.
J. Steim (1990)
Intravenous fat emulsions and the pancreas: a review.
A. Leibowitz (1992)
10.1016/0168-3659(94)90212-7
Lipid nano-sphere(LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. IV.
J. Seki (1994)
10.1016/0009-3084(94)90089-2
Synthesis and antiviral activity of 3'-azido-3'-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT.
G. M. van Wijk (1994)
10.1111/J.1600-0773.1995.TB00115.X
Cyclosporin A in fat emulsion carriers: experimental studies on pharmacokinetics and tissue distribution.
A. Tibell (1995)
10.1073/PNAS.82.20.7096
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H. Mitsuya (1985)
Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.
A. Rahman (1985)
10.1093/AJHP/34.10.1080
Clinical use of 10% soybean oil emulsion.
B. L. McNiff (1977)
10.1016/0009-3084(72)90017-5
The solid-liquid equilibrium of binary mixtures of triglycerides with palmitic and stearic chains
M. Knoester (1972)
10.1042/BJ1580473
Liposomal retention of a modified anti-inflammatory steroid.
I. Shaw (1976)
10.1200/JCO.1987.5.2.310
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
G. López-Berestein (1987)
10.1016/S0928-0987(97)86243-4
Solid lipid nanoparticles (SLN) for controlled drug delivery
R. Mueller (1996)
10.1016/0166-3542(94)90054-X
New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens.
R. Schwendener (1994)
10.1016/0378-5173(89)90173-7
Hydrolysis of phosphatidylcholine in aqueous liposome dispersions
M. Grit (1989)
Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low-density lipoprotein pathways.
H. Sqalli-Houssaini (1994)
10.1016/0005-2736(95)00218-9
Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.
J. Kamps (1996)
10.1016/0378-5173(83)90079-0
Solubilization and stabilization of an investigational antineoplastic drug (NSC no. 278214) in an intravenous formulation using an emulsion vehicle
A. A. El-Sayed (1983)
10.1002/CNE.901670102
Trans‐glial channels in ventral nerve roots of crayfish
R. Shivers (1976)
10.1016/0378-5173(93)90239-C
Liposome-incorporated dexamethasone palmitate: Chemical and physical properties
H. Benameur (1993)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
Polyhydroxybutyrate as a drug carrier.
F. Koosha (1989)
10.1002/JPS.2600790616
Ester prodrugs of zidovudine.
T. Kawaguchi (1990)
10.1111/j.1749-6632.1987.tb45793.x
Lipid Emulsions as Drug Delivery Systems
S. Davis (1987)
10.1016/0005-2736(93)90398-J
Characterization of 5-fluorouracil loaded liposomes prepared by reverse-phase evaporation or freezing-thawing extrusion methods: study of drug release.
B. Elorza (1993)
10.1016/0005-2760(95)00085-Q
Rate of release and retentivity of prostaglandin E1 in lipid emulsion.
T. Yamaguchi (1995)
10.1002/1097-0142(19950315)75:6<1245::AID-CNCR2820750606>3.0.CO;2-U
Arterial‐injection chemotherapy for hepatocellular carcinoma using monodispersed poppy‐seed oil microdroplets containing fine aqueous vesicles of epirubicin. Initial medical application of a membrane‐emulsification technique
S. Higashi (1995)



This paper is referenced by
10.1016/S0378-5173(02)00269-7
Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid.
Soo-Jeong Lim (2002)
Solid Lipid Nanoparticles: A Critical Appraisal
O. M. Bagade (2014)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1007/s12551-020-00750-0
An overview of polymeric nano-biocomposites as targeted and controlled-release devices.
Muhammad Rahim (2020)
10.1016/S0378-5173(02)00035-2
Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants, storage time and crystallinity.
C. Olbrich (2002)
10.1615/CRITREVTHERDRUGCARRIERSYST.2013005469
Nanomedicines for treatment of viral diseases.
Rujuta Mehendale (2013)
10.1155/2014/304757
A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms
Susan D'Souza (2014)
10.3390/nano10061085
Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
A. Murthy (2020)
10.1016/S0378-5173(98)00236-1
Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice
H. Heiati (1998)
10.4172/2155-983X.1000105
Preparation, Characterization and Cell Based Delivery of Stavudine Surface Modified Lipid Nanoparticles
R. Shegokar (2012)
10.3390/v4040488
Nanotechnology and the Treatment of HIV Infection
R. Parboosing (2012)
10.1007/s12272-009-1902-x
Analgesic, antipyretic, anti-inflammatory and toxic effects of andrographolide derivatives in experimental animals
Supawadee Suebsasana (2009)
Solid Lipid Nanoparticles as Indomethacin Carriers for Topical Use (2): DSC Analysis, Drug Release and Rheological Properties
H. M. A. Amara (2014)
Quantitative, Qualitative and In Vitro Evaluation of Solid Lipid Nanoparticles Containing 5-Fluorouracil
Mohamed S. Majrad (2014)
REVIEW OF SOLID LIPID NANOPARTICLES
Shereen Sultana (2020)
10.1016/j.addr.2009.11.018
Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
U. Gupta (2010)
FORMULATION OPTIMIZATION OF CITRONELLA GRASS OIL SOLID LIPID PARTICLES USING MIXTURE DESIGN
P. Lertsatitthanakorn (2013)
10.1007/978-0-387-77668-2_5
Drug Loading into and In Vitro Release from Nanosized Drug Delivery Systems
A. Judefeind (2009)
10.1002/JPS.20100
Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers.
H. L. Wong (2004)
10.1016/j.colsurfb.2008.12.031
Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles.
Hong Yuan (2009)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1166/JBN.2010.1169
Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs.
Sriharsha Gupta Potta (2010)
RECENT ADVANCES BASED ON SOLID LIPID NANOPARTICLE SYSTEMS FOR DELIVERY OF DRUGS
P. Dhanalakshmi (2012)
10.1016/J.ADDR.2012.09.021
Solid lipid nanoparticles
W. Mehnert (2012)
10.1071/CH16430
Effect of Modification Protocols on the Effectiveness of Gold Nanoparticles as Drug Delivery Vehicles for Killing of Breast Cancer Cells
Zahrah Alhalili (2016)
10.1007/S11483-008-9065-8
Solid Lipid Nanoparticles as Delivery Systems for Bioactive Food Components
J. Weiss (2008)
10.1080/07388550802107483
Production and Characterization of γ-Polyglutamic Acid Nanoparticles for Controlled Anticancer Drug Release
B. Manocha (2008)
10.1080/10717540802321776
Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy
T. Govender (2008)
Improving the chemical stability of beta-carotene and citral by nanoemulsions
Xiaoqing Yang (2012)
10.3109/10837450.2014.882935
Development and characterization of itraconazole-loaded solid lipid nanoparticles for ocular delivery
Biswaranjan Mohanty (2015)
A Review on Novel Delivery System: Solid Lipid Nanoparticles
(2019)
10.1007/978-981-32-9898-9_8
Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery
S. Saxena (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar